Loading
companiesCompany
Adventris Pharmaceuticals
Adventris Pharmaceuticals, a Johns Hopkins spin-out, develops off-the-shelf cancer vaccines designed to raise immune responses against mutant KRAS, the driver mutation shared by pancreatic, colorectal and lung cancers, with the long-term aim of a yearly vaccine that prevents those cancers before they form. Its programmes are preclinical or early clinical.
Overview
Adventris Pharmaceuticals, a Johns Hopkins spin-out, develops off-the-shelf therapeutic and preventive cancer vaccines using a platform designed to raise strong immune responses against poorly immunogenic oncogene-derived antigens. Its first vaccine targets mutant KRAS, relevant to pancreatic, colorectal and lung cancers, and the company's stated long-term vision is annual pan-cancer vaccination. Programmes are preclinical or early clinical; no sourced financing rounds are recorded here.
Headquarters
Baltimore, MD, US
Funding
All startupsStartupYC W23
Investors
Type
Stage
Startup · Y Combinator Winter 2023
Website
Similar pages
- CompanyTareBio
Shares Y Combinator, Off-the-shelf cancer vaccines and the tag yc.
- CompanyGuardian Bio
Shares Y Combinator, Off-the-shelf cancer vaccines and the tag yc.
- CompanyPersephone Biosciences
Shares Y Combinator, Colorectal cancer and the tag yc.
- CompanyAluna
Shares Y Combinator and the tag yc.
- CompanyMednet (theMednet)
Shares Y Combinator and the tag yc.
- CompanyCofactor Genomics
Shares Y Combinator, Non-small-cell lung cancer and the tag yc.
- CompanyAlixia
Shares Y Combinator and the tag yc.
- CompanyVelorum Therapeutics
Shares Y Combinator and the tag yc.